On May 8, the US Food and Drug Administration (FDA) granted accelerated approval to the combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

For more information, read the FDA announcement and the Verastem press release.

Posted on 5/19/2025